Slide 2

Patient-Focused Innovation

Kashiv BioSciences is a fully-integrated biopharmaceutical company developing advanced-stage biosimilars and complex products addressing unmet patient needs worldwide.

Slide 2

Robust R&D Capabilities

With end-to-end platform capabilities for small and large molecules, we develop programs across a range of therapeutic areas and regulatory pathways.

Slide 2

Carefully Crafted Pipeline

Our pipeline reflects our unique capabilities, featuring advanced-stage biosimilars, complex generics, 505(b)(2), and mRNA therapies.

previous arrow
next arrow
Shadow
Project Code
Global Sales ($B)
Therapeutic Area
Cell line & Process Development
Preclinical
Clinical
Submission
Approval
Commercial Partners

Biosimilar Pipeline

RELEUKO
$1.4
Oncology Supportive Care
Amneal for USA
FYLNETRA
$4.5
Oncology Supportive Care
Amneal for USA
ADL-018
$3.7
Immunology & Respiratory
KSHB001
$2.5
Digestive Care
KSHB002
$3.7
Immunology
KSHB004
$1.7
Cardiovascular
KSHB005
$15
Anti-Diabetic (T2DM)
KSHB006
$2.7
Immunology
KSHB007
$2.0
Fertility Hormone

Specialty Products

High value 505(b)(2) Pipeline

Project Code

Therapeutic Area

Early-stage development

Last-stage development

Est Filing Year

Partnership

KSHN010

Oncology

2023

Under Discussion

KSHN007

Gaucher’s Disease

2024

Open

Complex Generics

Project Code

Therapeutic Area

Early-stage development

Last-stage development

Est Filing Year

Partnership

KSHG004

Fertility Peptide

2023

Amneal

KSHG005

Fertility Peptide

2022

Amneal

KSHG006

Long acting peptide

2023

Open

KSHN007

Gaucher’s Disease

2024

Open

NCEs Pipeline

Project Code

Therapeutic Area

Proof Of Concept

Hit and Lead Identification

Lead Optimization

Candidate Selection

pre-IND & IND Enabling Studies

IND Filing

KSHG001

Oncology (Oral Candidate)

2022

KSHG001

Oncology (Injectable Candidate)

2022

KSHG002

Interstitial Cystitis

2023

KSHG016

Parkinson’s Disease

TBD

Research Topic

Medical, Medicine and Health
Science Topic

01

Contact To
Test

02

Lab Generates
Proposal

03

Get Clean &
Fresh

04

Enjoy Our
Service

Lets Watch Our Recent Work

Clinical Services

Explore Our Main Services.

Clinical Microbiology
Tests

Excepteur sint ocecat pro sunt in culpa. qui officia deserunt mollit anim id est. perspiciatis unde.

Testing for Traces &
Impurities

Excepteur sint ocecat pro sunt in culpa. qui officia deserunt mollit anim id est. perspiciatis unde.

Clinical Biochemistry
Tests

Excepteur sint ocecat pro sunt in culpa. qui officia deserunt mollit anim id est. perspiciatis unde.

0+
Permanent Staff
0k+
Test Completed
0+
Wining Awards
0k+
Years Of Exps.
Testimonials

What Our Patient Say?

Team Member

Focusing Your Mind, with The
Best Expert.

Accurate Product Testing
by Expert Scientists

PISCATAWAY, New Jersey

Kashiv BioSciences’ 50,000 sq. ft. R&D facility has capabilities for mammalian cell line development, advanced analytical characterization, bioassay development, and small-scale manufacturing of complex proteins and monoclonal antibodies.
Analytical Characterization Lab
Cell Line Process Development
Biosimilar R&D Facility

CHICAGO, ILlinois

Kashiv BioSciences’ 100,000 sq.ft. R&D and manufacturing facility has capabilities for development and manufacturing of commercial-scale microbial cell lines, drug substance, and a fill and finish line for prefilled syringes and vials. It is an FDA-registered site and complies fully with Local, State, and Federal Agencies, OSHA, EPA, and cGMP Standards.
Upstream Production Suite
Injectable Fill and Finish Line
Biosimilar R&D and Injectable Manufacturing Facility

AHMEDABAD, GUJARAT, INDIA

Kashiv BioSciences’ 125,000 sq.ft. R&D facility contains state-of-the-art analytical labs for characterization, stability, bioassay development, process development, and small scale manufacturing of complex proteins for biosimilars. This site also conducts R&D for prodrugs and 505(b)(2) programs.
India office and R&D facility
Advanced analytical suites for biosimilar, 505(b)(2), and prodrug development
Analytical labs equipped with the latest technology